Modulation of P-glycoprotein function by amlodipine derivatives in brain microvessel endothelial cells of rats

被引:0
作者
Bian-sheng Ji
Ling He
Guo-qing Liu
机构
[1] China Pharmaceutical University,Department of Pharmacology
来源
Acta Pharmacologica Sinica | 2005年 / 26卷
关键词
amlodipine derivatives; CJX1; CJX2; verapamil; P-glycoprotein; blood brain barrier; vascular endothelium;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:166 / 170
页数:4
相关论文
共 61 条
[1]  
Germann UA(1996)P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A 927-44
[2]  
Gottesman MM(1993)Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62 385-427
[3]  
Pastan I(2004)PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 10 1493-503
[4]  
Elsinga PH(2003) saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier. Pharm Res 20 1607-11
[5]  
Hendrikse NH(2002)Effect of endotoxin on doxorubicin transport across blood-brain barrier and P-glycoprotein function in mice. Eur J Pharmacol 445 115-23
[6]  
Bart J(1994) evidence for ATP-dependent and P-glycoprotein- mediated transport of cyclosporin A at the blood-brain barrier. Biochem Pharmacol 48 1989-92
[7]  
Vaalburg W(1988)Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins. Br J Cancer 57 254-8
[8]  
van Waarde A(1999)Combinations of P-glyco-protein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res 19 1053-64
[9]  
Cisternino S(2003)Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol 42 S71-4
[10]  
Rousselle C(2000)Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res 17 1189-97